Pimozide is similarly effective against cells with unmutated BCR/ABL and kinase inhibitor-resistant T315I mutant BCR/ABL. (A) The 32d cells reconstituted with the T315I mutant form of BCR/ABL were treated for 3 hours with pimozide (5μM), after which RNA was harvested, and expression of the indicated genes was measured using quantitative RT-PCR and normalized to the expression of β-actin. (B) The 32d cells reconstituted with unmutated BCR/ABL (p210) or BCR/ABL with the kinase inhibitor-resistant T315I mutation were treated with pimozide at the indicated concentration for 48 hours after which viable cell number was measured by ATP dependent bioluminescence.